With the rapid advancement in oncology research, numerous treatment approaches have been implemented in cancer patients. These approaches include chemotherapy, radiation therapy, targeted therapy, immunotherapy, and others. These treatments work by either destroying cancer cells or impeding their growth, and they can be administered individually or in combination to yield optimal outcomes. However, a significant challenge in cancer management is the development of resistance to these anti-cancer therapies. Unfortunately, the precise mechanism underlying drug resistance in cancer remains largely obscure.

This Research Topic aims to elucidate the molecular mechanisms responsible for drug resistance in cancers. It specifically focuses on exploring new molecular biomarkers, novel targets, and potential drugs. The research community must investigate both common and specific molecular biomarkers along with novel targets to achieve this objective. By identifying the role of molecular mechanisms in mediating therapy resistance, we can significantly enhance the efficacy of cancer treatments.

We welcome original research, reviews, mini-reviews, and perspective manuscripts covering a wide range of areas, including but not limited to:

• Exploration of novel molecular biomarkers and/or drug targets that regulate drug resistance in cancer patients.
• Identification of molecular pathways that govern the sensitivity or resistance to anti-cancer therapy.
• Utilization of high-throughput methods, such as mass spectrometry and Genome-Wide Association Studies, to screen for molecular targets and potential drugs that can enhance the effectiveness of anti-cancer therapies.
• Conducting clinical studies, such as cohort studies or Randomized Controlled Trials (RCTs), to confirm the efficiency of molecular targets in overcoming drug resistance in cancers.
• Development of new drug delivery methods based on novel molecular targets to counter drug resistance in cancers.

Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases, without independent validation (either through cohort studies or in vitro/in vivo experimentation), are beyond the scope of this section and will not be accepted as part of this Research Topic.

Submit your idea

Impact

Frontiers in Pharmacology

Participating Journals

Submit your idea

Impact